Mar 1, 2026 Log in

News

All Cosmos Bio-Tech (ACB-KY) March 2026 Revenue NT$214 million (YoY -18.6%)

Citation-Grade Primary-source linked Schema.org verified NQ 6 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Mar 1, 2026 9:00 AM ・ Updated Jun 1, 2026 1:10 PM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

All Cosmos Bio-Tech's monthly revenue for March 2026 was NT$214 million, a decrease of 18.6% year-over-year.
The company is classified in the biotechnology and medical care industry.

All Cosmos Bio-Tech's monthly revenue for March 2026 was NT$214 million, a decrease of 18.6% year-over-year. The company is classified in the biotechnology and medical care industry.

PRIMARY SOURCE Original source: https://openapi.twse.com.tw/revenue/twse-rev-4148-11503 Distributor: PR Times
Published: Mar 1, 2026

All Cosmos Bio-Tech (ACB-KY) (Stock Code: 4148), a company in the Biotechnology and Medical Care industry, announced its revenue for March 2026. The monthly revenue reached 213,712 thousand NTD (approximately NT$214 million), which marks an 18.6% decrease compared to the same month last year.

FACT BOX

Source: PR Times
Category: News

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Mar 1, 2026 9:00 AM — Distributor PR Times
Collected　Apr 12, 2026 4:30 PM
AI structured & analyzed　Apr 12, 2026 9:27 PM
Desk-reviewed & published　Mar 1, 2026 9:00 AM

FAQ

What are the key facts in this article?

All Cosmos Bio-Tech's monthly revenue for March 2026 was NT$214 million, a decrease of 18.6% year-over-year. The company is classified in the biotechnology and medical care industry.

Where is the primary source?

PR Times: https://openapi.twse.com.tw/revenue/twse-rev-4148-11503

When was it published?

Mar 1, 2026

Cite this article — HOW TO CITE

Washin AI News Desk“All Cosmos Bio-Tech (ACB-KY) March 2026 Revenue NT$214 million (YoY -18.6%)”AI News by Washin Village（和心村）, Mar 1, 2026. https://aeo.washinmura.jp/ai/%E5%85%A8%E5%AE%87%E7%94%9F%E6%8A%80-ky/en/news/2026-03-01-all-cosmos-bio-tech-acb-ky-march-2026-re

AI CRAWLER ACTIVITY

as of Jul 18, 2026

AI crawler visits to this article (cumulative)103 bots

Site-wide cumulative

Applebot

bot_visits_summary

4300k

last Jul 18, 2026

ClaudeBot

bot_visits_summary

2942k

last Jul 18, 2026

GPTBot

bot_visits_summary

2549k

last Jul 18, 2026

Bingbot

bot_visits_summary

2429k

last Jul 18, 2026

Meta AI

bot_visits_summary

1037k

last Jul 18, 2026

Google AI

bot_visits_summary

581k

last Jul 18, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 全宇生技-ky Back to newsroom (57)

Copied